Final EMA oracle [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2010-02-01 14:43 (5978 d 06:54 ago) – Posting: # 4678
Views: 27,623

Dear ElMaestro!

❝ Contrary to HS' opinion, I think this is exactly how that sentence should be interpreted for now.


Do I get you right - really like this one?

In Bonn last year we had a heated debate about the proposed 4-way fed/fasted study.
+-----+-------+-------+-------+-------+
| S/P |   1   |   2   |   3   |   4   |
+-----+-------+-------+-------+-------+
|  1  | R-fed | R-fst | T-fst | T-fed |
|  2  | T-fst | R-fed | T-fed | R-fst |
|  3  | T-fed | T-fst | R-fst | R-fed |
|  4  | R-fst | T-fed | R-fed | T-fst |
+-----+-------+-------+-------+-------+

Do you believe, that EMA wants us to come up with 4 separate pseudo-2×2 cross-over studies (T-fst/R-fst, T-fed/R-fed, T-fed/T-fst, R-fed/R-fst)?

Forget about the tricky things (imbalance, sequence/carry-over), but what about the period effect, which does not influence the treatment effect in a 2×2 cross-over? But here; probably apples-and-oranges.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
119 visitors (0 registered, 119 guests [including 15 identified bots]).
Forum time: 22:37 CEST (Europe/Vienna)

The idea is to try and give all the information to help others
to judge the value of your contribution;
not just the information that leads to judgment
in one particular direction or another.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5